CA2232059A1 - Derives du phenol a activite pharmaceutique - Google Patents

Derives du phenol a activite pharmaceutique Download PDF

Info

Publication number
CA2232059A1
CA2232059A1 CA002232059A CA2232059A CA2232059A1 CA 2232059 A1 CA2232059 A1 CA 2232059A1 CA 002232059 A CA002232059 A CA 002232059A CA 2232059 A CA2232059 A CA 2232059A CA 2232059 A1 CA2232059 A1 CA 2232059A1
Authority
CA
Canada
Prior art keywords
piperidin
fluorophenyl
compound
hydroxyl
chroman
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002232059A
Other languages
English (en)
Inventor
Bertrand Leo Chenard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2232059A1 publication Critical patent/CA2232059A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composés de la formule (I) et sels de ces composés acceptables d'un point de vue pharmaceutique, formule dans laquelle R est tel que le définit la description, lesdits composés et sels constituant des promédicaments pour un antagoniste compétitif d'acide N-méthyl D-aspartique (NMDA), qui bloque les sites récepteurs de NMDA et est utile dans le traitement de certains états et certaines maladies réagissant au blocage de sites récepteurs de NMDA, tels que le traumatisme crânien, l'attaque, la démence due à des infarctus multiples, ou d'autres troubles.
CA002232059A 1995-09-15 1996-07-11 Derives du phenol a activite pharmaceutique Abandoned CA2232059A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US385495P 1995-09-15 1995-09-15
US60/003,854 1995-09-15

Publications (1)

Publication Number Publication Date
CA2232059A1 true CA2232059A1 (fr) 1997-03-20

Family

ID=21707913

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002232059A Abandoned CA2232059A1 (fr) 1995-09-15 1996-07-11 Derives du phenol a activite pharmaceutique

Country Status (4)

Country Link
EP (1) EP0859773A1 (fr)
JP (1) JPH11509839A (fr)
CA (1) CA2232059A1 (fr)
WO (1) WO1997010240A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017093354A1 (fr) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes de nmdar pour le traitement de maladies associées à l'angiogenèse

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0741724B1 (fr) * 1994-01-31 1999-08-11 Pfizer Inc. Composes de chromane neuroprotecteurs

Also Published As

Publication number Publication date
WO1997010240A1 (fr) 1997-03-20
MX9802025A (es) 1998-08-30
JPH11509839A (ja) 1999-08-31
EP0859773A1 (fr) 1998-08-26

Similar Documents

Publication Publication Date Title
EP2970123B1 (fr) Sel de omecamtiv mecarbil et son procédé de préparation
AU2002350869B2 (en) Polymorphous form of rimonabant, preperation method and pharmaceutical compositions containing same
WO1992018504A1 (fr) DERIVE DE PYRAZOLO[1,5-a]PYRIMIDINE ET AGENT ANTI-INFLAMMATOIRECONTENANT CE DERIVE
US20030036559A1 (en) Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3-[2- (2-methoxyphenoxy) -ethylamino] -2-propanole process for its preparation and pharmaceutical compositions containing it
CZ391091A3 (en) Crystalline paroxetin hydrochloride hemihydrate, process for producing thereof and pharmaceutical preparations in which it is comprised
CA3226980A1 (fr) Procede de preparation d'un derive de tryptamine
CA2087091C (fr) Antagonistes d'acides amines excitateurs
JPH10182583A (ja) 新規ヒドロキサム酸誘導体
CZ296947B6 (cs) Modifikace (+-)1-(4-karbazolyloxy)-3-[2-(2-methoxyfenoxy)ethylamino]-2-propanolu, zpusob její prípravy a izolace, farmaceutický prostredek s jejím obsahem a jeho pouzití
CN102234287B (zh) 硝基咪唑类化合物、其制备方法和用途
EP0529654A1 (fr) Dérivés de benzopyranne comme activateurs des canaux de potassium et inhibiteurs de 5-lipoxygénase
EP0163537A1 (fr) Dérivés de la propanone-1 et compositions pharmaceutiques les contenant
US8785663B2 (en) Polymorphic forms of Lubiprostone
JPH0536436B2 (fr)
JPH02189A (ja) １‐アミノメチルホスホン酸誘導体、その製造法および医薬組成物
NO301162B1 (no) Imidazolylpyridinderivater
EP1790643B1 (fr) Composes de quinuclidine a groupe ammonium quaternaire, procede d'elaboration et utilisation comme agents de blocage de l'acetycholine
IL197962A (en) Crystalline form of –3– (1 h– indole – 3 – yl) –4– [2– (4 – methyl – piperazine – 1 – yl) –quinazoline – 4 – yl] –pyrol – 2,5 – deion acetate, preparation A medical containing it, a process for its preparation and its use in the preparation of pharmacological material
JP3694774B2 (ja) フェニルカルボン酸誘導体
JPH04316557A (ja) ６−アリール環状アントラニル酸誘導体
CA2446763A1 (fr) Nouveaux derives 5-thio-ss-d-xylopyranosides, procede de preparation, compositions pharmaceutiques les contenant et leur utilisation en therapeutique
CN111620816A (zh) 螺桨烷类衍生物、其制备方法、药物组合物和用途
US5137908A (en) 4-azahexacyclododecane compounds
JP2790335B2 (ja) 共役γ―オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤
KR101172472B1 (ko) 4급 암모늄 화합물, 그 제조 방법, 뇌혈관 장애 치료제 및 심장 질환 치료제

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead